This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Read the original research
Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.
Diabetes, obesity & metabolism, 25(10), 2805-2814
Citation
Saxena, Aditi R; Frias, Juan P; Gorman, Donal N; Lopez, Rene N; Andrawis, Nabil; Tsamandouras, Nikolaos; Birnbaum, Morris J. (2023). Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes.. Diabetes, obesity & metabolism, 25(10), 2805-2814. https://doi.org/10.1111/dom.15168